Cart
sales@molnova.com
IRES-C11
CAS No. 342416-30-2
IRES-C11( IRES inhibitor C11 )
Catalog No. M14164 CAS No. 342416-30-2
A novel, spectfic c-Myc IRES (internal ribosome entry site) function inhibitor that prevents binding of hnRNP A1 to the Myc IRES and specifically inhibits Myc IRES activity in MM cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 258 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 376 | In Stock |
|
| 25MG | 748 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | 1730 | In Stock |
|
| 200MG | 2316 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIRES-C11
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel, spectfic c-Myc IRES (internal ribosome entry site) function inhibitor that prevents binding of hnRNP A1 to the Myc IRES and specifically inhibits Myc IRES activity in MM cells.
-
DescriptionA novel, spectfic c-Myc IRES (internal ribosome entry site) function inhibitor that prevents binding of hnRNP A1 to the Myc IRES and specifically inhibits Myc IRES activity in MM cells; shows no effect on BAG-1, XIAP and p53 IRESes, and has no significant effect on myc translation; significantly inhibits myc expression when combined with ER stress inducers, especially bortezomib; shows synergistic anti-MM cytotoxicity combined with ER stress inducers; also blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-GBM properties combined with PP242.
-
In VitroIRES-C11 blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-glioblastoma properties when combined with the mechanistic target of mTOR PP242.IRES-C11 (50 nM) significantly inhibits both cyclin D1 and c-MYC IRES activity. IRES-C11 treatment induces a significant shift in both cyclin D1 and c-MYC mRNA to monosomal/nonribosomal fractions, whereas actin mRNA distribution is unaffected. IRES-C11 inhibits both cyclin D1 and c-MYC IRES-mediated mRNA translation, leading to reductions in protein levels.Mechanistic studies with IRES-C11 reveal binding of the inhibitors within the UP1 fragment of heterogeneous nuclear ribonucleoprotein A1.
-
In Vivo——
-
SynonymsIRES inhibitor C11
-
PathwayCell Cycle/DNA Damage
-
Targetc-Myc
-
Recptorc-Myc
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number342416-30-2
-
Formula Weight316.134
-
Molecular FormulaC13H11Cl2NO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (790.79 mM)
-
SMILESCOC1=CC(=C(C=C1)CN2C(=O)C(=C(C2=O)Cl)Cl)OC
-
Chemical Name3,4-dichloro-1-(2,4-dimethoxybenzyl)-1H-pyrrole-2,5-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
10058-F4
10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.
-
MYCi361
MYCi361 is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values.
-
MYCi975
MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.
